Present Phase 2a clinical trial data for 23ME-00610
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Jan 2024
- Due
- 30 Jun 2024
- Delivered
- by 3 Jun 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Ph2a data expected to be presented mid- 2024”
What we found
Evidence strength A What the grades mean
The company presented Phase 2a clinical trial data for 23ME-00610 at the ASCO annual meeting, which took place in early June 2024, meeting the mid-2024 deadline.
-
A 23andMe Holding Co. 8-K filed 2024-08-08
“Presented posters at ASCO on the neuroendocrine cohort and ovarian cohort for 23ME-00610, the first data presentations from the Phase 2a expansion cohorts.” ✓ confirmed on the page
Checked 25 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you 23andMe Holding Co.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-C804591-000001 · Corrections policy